RxDoctor Payments Data

Jillian Brito, APRN

Nurse Practitioner · Coral Gables, FLNPI 1497294458

Payments from drug & device makers

$5,459in general payments, 2019–2025

Across 269 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ardelyx, Inc.$948
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$754
  • AbbVie$569
  • Takeda Pharmaceuticals U.S.A., Inc.$446
  • Phathom Pharmaceuticals, Inc.$444
  • Johnson & Johnson$399
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$5,29497%
  • Education$1653%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,459 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$12,941
Medicare patients
82
Services billed
114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide206$176,329
CreonLipase/Protease/Amylase70$146,271
ZenpepLipase/Protease/Amylase53$141,827
Humira PenAdalimumab12$82,986
IbsrelaTenapanor Hcl24$48,381
XifaxanRifaximin14$31,442
TrulancePlecanatide41$28,948
Dexlansoprazole DrDexlansoprazole69$14,655
VoqueznaVonoprazan Fumarate21$13,151
Famotidine697$9,347
CholestyramineCholestyramine (With Sugar)69$7,023
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates93$5,657
Rifabutin18$4,421
Sucralfate47$3,834
ClenpiqSod Picosulf/Mag Ox/Citric Ac21$3,652

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$569$322,599276 claims
Aimmune Therapeutics, Inc.Zenpep$149$141,82753 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$754$60,39055 claims
Ardelyx, Inc.Ibsrela$948$48,38124 claims
Phathom Pharmaceuticals, Inc.Voquezna$444$13,15121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Coral Gables

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →